Are there any ongoing clinical trials using proteomics as a diagnostic test?
A NCI-sponsored ovarian cancer clinical trial, involving ten sites, is scheduled to start in Fall 2005. Because over 80 percent of advanced stage epithelial ovarian cancer patients see their cancer return after being treated with standard chemotherapy, biomarkers are needed for predictors of persistent disease and relapse. CA-125, the only FDA-approved ovarian cancer relapse marker, will become elevated in some, but not all, of the approximately 80 percent of advanced stage patients for whom it was increased at initial diagnosis. Elevation in CA-125 may precede clinical evidence of relapse by as much as six to 10 months or lag behind clinical relapse by the same time intervals, making it a less than satisfactory clinical tool. Researchers have identified a protein signature pattern that sensitively and specifically recognizes the presence of ovarian cancer (stages I-IV) in blood from affected women. Furthermore, the pattern can distinguish between affected women and unaffected women an
A NCI-sponsored ovarian cancer clinical trial, involving ten sites, is scheduled to start in Fall 2005. Because over 80 percent of advanced stage epithelial ovarian cancer patients see their cancer return after being treated with standard chemotherapy, biomarkers are needed for predictors of persistent disease and relapse. CA-125, the only FDA-approved ovarian cancer relapse marker, will become elevated in some, but not all, of the approximately 80 percent of advanced stage patients for whom it was increased at initial diagnosis. Elevation in CA-125 may precede clinical evidence of relapse by as much as six to 10 months or lag behind clinical relapse by the same time intervals, making it a less than satisfactory clinical tool. Researchers have identified a protein signature pattern that sensitively and specifically recognizes the presence of ovarian cancer (stages I-IV) in blood from affected women. Furthermore, the pattern can distinguish between affected women and unaffected women an
